Highlights•BRAF alterations lead to unbridled activation of the MAPK pathway which can
result in cancer development and progression.•BRAF and MEK inhibitors led to paradigm …

Genomic profiling shows that many solid tumors are characterized by specific driver
aberrations, and this has expanded the therapeutic options for many patients. The mitogen …

Abstract The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated
pathways in human cancer. Approximately 50% of melanoma patients possess a druggable …

The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …

BRAF plus MEK inhibitor combinations are currently FDA-approved for melanoma, non–
small cell lung cancer, and anaplastic thyroid cancer. The lack of clinical benefit with BRAF …

Mitogen-activated protein kinase (MAPK) activation is a common property of human cancers
and is often due to activating mutations in the BRAF and RAS genes. BRAF kinase domain …

Background Oncogenic BRAF mutations have been found in diverse malignancies and
activate RAF/MEK/ERK signaling, a critical pathway of tumorigenesis. We examined the …

Serine/threonine-protein kinase BRAF, a downstream effector of the RAS oncogene along
the MEK/ERK signaling pathway, has emerged as an important biological marker for …

Abstract Mitogen Activated Protein Kinase (MAPK) pathway activation is a frequent event in
human cancer and is often the result of activating mutations in the BRAF and RAS …

Opinion Statement BRAF mutations are present in up to 8% of human cancers, and
comprise a viable therapeutic target in many patients harboring these mutations. Specific …